Are you Dr. Zhou?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 8 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
33608 Ortega Hwy
San Juan Capistrano, CA 92675Phone+1 949-728-4188- Is this information wrong?
Summary
- Dr. Weidong Zhou, MD is a board certified pathologist in San Juan Capistrano, California. She is currently licensed to practice medicine in California, Texas, and Colorado.
Education & Training
- University of California (Irvine)Residency, Pathology-Anatomic and Clinical, 1997 - 2001
- Nanjing Medical UniversityClass of 1988
Certifications & Licensure
- AZ State Medical License 2009 - 2026
- CA State Medical License 1998 - 2026
- FL State Medical License 2009 - 2026
- MI State Medical License 2009 - 2025
- CO State Medical License 2010 - 2025
- TX State Medical License 2011 - 2025
- KS State Medical License 2009 - 2024
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsInhibitors of Venezuelan Equine Encephalitis Virus Identified Based on Host Interaction Partners of Viral Non-Structural Protein 3Allison Bakovic, Nishank Bhalla, Farhang Alem, Catherine E. Campbell, Weidong Zhou, Aarthi Narayanan> ;Viruses. 2021 Aug 3
- Use of magnetic nanotrap particles in capturing Yersinia pestis virulence factors, nucleic acids and bacteria.Alexandra N. Ii, Shih-Chao Lin, Benjamin Lepene, Weidong Zhou, Kylene Kehn-Hall, Monique L. van Hoek> ;Journal of Nanobiotechnology. 2021 Jun 21
- 9 citationsProteomic Discovery of VEEV E2-Host Partner Interactions Identifies GRP78 Inhibitor HA15 as a Potential Therapeutic for Alphavirus Infections.Michael D. Barrera, Victoria Callahan, Ivan V. Akhrymuk, Nishank Bhalla, Weidong Zhou, Catherine E. Campbell, Aarthi Narayanan, Kylene Kehn-Hall> ;Pathogens. 2021 Mar 2
- Join now to see all
Press Mentions
- Characterization and Validation of Arg286 Residue of IL-1RAcP as a Potential Drug Target for OsteoarthritisFebruary 3rd, 2021